{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:35:07Z","timestamp":1782995707613,"version":"3.54.5"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["137965"],"award-info":[{"award-number":["137965"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001322","name":"Medical Research Council of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001323","name":"Poliomyelitis Research Foundation","doi-asserted-by":"publisher","award":["23\/78"],"award-info":[{"award-number":["23\/78"]}],"id":[{"id":"10.13039\/501100001323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.nmni.2026.101735","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:20:23Z","timestamp":1772526023000},"page":"101735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A review of the current anti-Cryptococcus antifungals and emerging treatment strategies"],"prefix":"10.1016","volume":"70","author":[{"given":"Maphori","family":"Maliehe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulina M.","family":"Rapeso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khwezi","family":"Mdana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen K.","family":"McQuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lebogang","family":"Moukangwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nolwazi F.","family":"Ntshangase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozethu","family":"Mjokane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zothile T.","family":"Skosana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adepemi O.","family":"Ogundeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olufemi S.","family":"Folorunso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina H.","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobus","family":"Albertyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-1084","authenticated-orcid":false,"given":"Olihile M.","family":"Sebolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmni.2026.101735_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nrmicro.2015.6","article-title":"Cryptococcus: from environmental saprophyte to global pathogen","volume":"14","author":"May","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.nmni.2026.101735_bib2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S1473-3099(22)00656-9","article-title":"Diagnostic capacity for invasive fungal infections in advanced HIV disease in Africa: a continent-wide survey","volume":"23","author":"Lakoh","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib3","series-title":"Cryptococcus neoformans","author":"Casadevall","year":"1998"},{"key":"10.1016\/j.nmni.2026.101735_bib4","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/myc.13440","article-title":"Cryptococcosis in the Democratic Republic of Congo from 1953 to 2021: a systematic review and meta-analysis","volume":"65","author":"Zono","year":"2022","journal-title":"Mycoses"},{"key":"10.1016\/j.nmni.2026.101735_bib5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1128\/jb.175.5.1405-1411.1993","article-title":"Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA","volume":"175","author":"Toffaletti","year":"1993","journal-title":"J Bacteriol"},{"key":"10.1016\/j.nmni.2026.101735_bib6","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/675213","article-title":"Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: an atlas of the molecular types","author":"Cogliati","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.nmni.2026.101735_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17530059.2012.681300","article-title":"CrAg lateral flow assay for cryptococcosis","volume":"6","author":"Kozel","year":"2012","journal-title":"Expert Opin Med Diagn"},{"key":"10.1016\/j.nmni.2026.101735_bib8","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02261-19","article-title":"Comparison of MIC test strip and sensititre YeastOne with the CLSI and EUCAST broth microdilution reference methods for in vitro antifungal susceptibility testing of Cryptococcus neoformans","volume":"64","author":"Delma","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib9","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/cid\/ciy971","article-title":"Healthcare costs and life-years gained from treatments within the advancing Cryptococcal meningitis treatment for Africa (ACTA) trial on cryptococcal meningitis: a comparison of antifungal induction strategies in Sub-Saharan Africa","volume":"69","author":"Chen","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib10","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.nmni.2026.101735_bib11","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1473-3099(17)30243-8","article-title":"Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis","volume":"17","author":"Rajasingham","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib12","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/S1473-3099(22)00499-6","article-title":"The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis","volume":"22","author":"Rajasingham","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib13","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s11011-013-9476-1","article-title":"Predictors of neurocognitive outcomes on antiretroviral therapy after cryptococcal meningitis: a prospective cohort study","volume":"29","author":"Carlson","year":"2014","journal-title":"Metab Brain Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib14","series-title":"WHO fungal priority pathogens list to guide research, development and public health action","year":"2022"},{"key":"10.1016\/j.nmni.2026.101735_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0032278","article-title":"Antifungal susceptibility profiles of 1698 yeast reference strains revealing potential emerging human pathogens","volume":"7","author":"Desnos-Ollivier","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nmni.2026.101735_bib16","series-title":"Guidelines for diagnosing, preventing and managing cryptococcal disease among adults, adolescents and children living with HIV","year":"2022"},{"key":"10.1016\/j.nmni.2026.101735_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.nmni.2026.101735_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/jof6040321","article-title":"Amphotericin B and other polyenes - discovery, clinical use, mode of action and drug resistance","volume":"6","author":"Carolus","year":"2020","journal-title":"J Fungi"},{"key":"10.1016\/j.nmni.2026.101735_bib19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/jac\/dkh434","article-title":"Combinations of antifungal agents in therapy\u2013what value are they?","volume":"54","author":"Cuenca-Estrella","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-017-04588-7","article-title":"High-dose fluconazole in combination with amphotericin B is more efficient than monotherapy in murine model of cryptococcosis","volume":"7","author":"Santos","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmni.2026.101735_bib21","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1086\/599112","article-title":"A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib22","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","article-title":"Combination antifungal therapy for cryptococcal meningitis","volume":"368","author":"Day","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2026.101735_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/jac\/46.2.171","article-title":"Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions","volume":"46","author":"Vermes","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM199707033370103","article-title":"Treatment of cryptococcal meningitis associated with acquired immunodeficiency syndrome","volume":"337","author":"van der Horst","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2026.101735_bib25","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1710922","article-title":"Antifungal combinations for treatment of cryptococcal meningitis in Africa","volume":"378","author":"Molloy","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2026.101735_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-015-1023-8","article-title":"Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib27","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1128\/AAC.01299-15","article-title":"Increased antifungal drug resistance in clinical isolates of Cryptococcus neoformans in Uganda","volume":"59","author":"Smith","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008137","article-title":"Decreasing fluconazole susceptibility of clinical South African Cryptococcus neoformans isolates over a decade","volume":"14","author":"Naicker","year":"2020","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2021.723251","article-title":"High prevalence of HIV-related cryptococcosis and increased resistance to fluconazole of the Cryptococcus neoformans complex in Jiangxi Province, South Central China","volume":"11","author":"Yang","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.nmni.2026.101735_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4102\/sajhivmed.v20i1.1030","article-title":"Southern African HIV Clinicians society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 update","volume":"20","author":"Govender","year":"2019","journal-title":"South Afr J HIV Med"},{"key":"10.1016\/j.nmni.2026.101735_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1056\/NEJM197907193010303","article-title":"A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis","volume":"301","author":"Bennett","year":"1979","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmni.2026.101735_bib33","article-title":"Evaluating the use of lower dose flucytosine for the treatment of cryptococcal meningitis: a clinical trial","author":"Rutakingirwa","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib34","article-title":"A trial to understand how a new formulation of flucytosine works in the body among people with early cryptococcal disease","year":"2024","journal-title":"Identifier: ISRCTN18180872"},{"key":"10.1016\/j.nmni.2026.101735_bib36","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nbt0712-571a","article-title":"NCATS launches drug repurposing program","volume":"30","author":"Allison","year":"2012","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.nmni.2026.101735_bib37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1358\/dnp.2009.22.2.1343228","article-title":"The value of drug repositioning in the current pharmaceutical market","volume":"22","author":"Tobinick","year":"2009","journal-title":"Drug News Perspect"},{"key":"10.1016\/j.nmni.2026.101735_bib38","first-page":"S127","article-title":"Drug repurposing: new tricks for old drugs. South African","volume":"28","author":"Gayaparsad","year":"2022","journal-title":"J Anaesth Analg"},{"key":"10.1016\/j.nmni.2026.101735_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug repurposing: an effective tool in modern drug discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ J Bioorg Chem"},{"key":"10.1016\/j.nmni.2026.101735_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028025","article-title":"Systematic drug repositioning based on clinical side-effects","volume":"6","author":"Yang","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nmni.2026.101735_bib41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1208\/s12248-012-9390-1","article-title":"Drug repurposing: far beyond new targets for old drugs","volume":"14","author":"Oprea","year":"2012","journal-title":"AAPS J"},{"key":"10.1016\/j.nmni.2026.101735_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-017-0128-7","article-title":"Large-scale detection of drug off-targets: hypotheses for drug repurposing and understanding side-effects","volume":"18","author":"Chartier","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.nmni.2026.101735_bib43","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1128\/EC.00314-12","article-title":"A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis","volume":"12","author":"Butts","year":"2013","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.nmni.2026.101735_bib44","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1021\/acsinfecdis.7b00157","article-title":"Antifungal phenothiazines: optimization, characterization of mechanism, and modulation of neuroreceptor activity","volume":"4","author":"Montoya","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib45","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/emboj\/16.10.2576","article-title":"Calcineurin is required for virulence of Cryptococcus neoformans","volume":"16","author":"Odom","year":"1997","journal-title":"EMBO J"},{"key":"10.1016\/j.nmni.2026.101735_bib46","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1128\/AAC.02810-15","article-title":"Repurposing of aspirin and ibuprofen as candidate anti-cryptococcus drugs","volume":"60","author":"Ogundeji","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib47","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1128\/AAC.00212-12","article-title":"The antidepressant sertraline provides a promising therapeutic option for neurotropic cryptococcal infections","volume":"56","author":"Zhai","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib48","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/mmy\/myv109","article-title":"Activity of sertraline against Cryptococcus neoformans: in vitro and in vivo assays","volume":"54","author":"Trevi\u00f1o-Rangel","year":"2016","journal-title":"Med Mycol"},{"key":"10.1016\/j.nmni.2026.101735_bib49","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1473-3099(16)00074-8","article-title":"Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study","volume":"16","author":"Rhein","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib50","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1473-3099(19)30127-6","article-title":"Adjunctive sertraline in HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trial","volume":"19","author":"Rhein","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib51","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/myc.12995","article-title":"Short course amphotericin B in addition to sertraline and fluconazole for treatment of HIV-associated cryptococcal meningitis in rural Tanzania","volume":"62","author":"Katende","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.nmni.2026.101735_bib52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(02)00711-8","article-title":"The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators","volume":"3","author":"Regan","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.nmni.2026.101735_bib53","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1128\/AAC.01564-08","article-title":"Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization","volume":"53","author":"Dolan","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib54","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/myc.12955","article-title":"The combination of tamoxifen with amphotericin B, but not with fluconazole, has synergistic activity against the majority of clinical isolates of Cryptococcus neoformans","volume":"62","author":"Hai","year":"2019","journal-title":"Mycoses"},{"key":"10.1016\/j.nmni.2026.101735_bib55","article-title":"An open label randomized controlled trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis","volume":"10","author":"Ngan","year":"2021","journal-title":"Microbiol Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib56","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s12223-023-01040-4","article-title":"In vitro and in vivo synergistic effects of hydroxychloroquine and itraconazole on Cryptococcus neoformans","volume":"68","author":"Wang","year":"2023","journal-title":"Folia Microbiol (Praha)"},{"key":"10.1016\/j.nmni.2026.101735_bib57","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1128\/AAC.41.4.802","article-title":"Enhanced resistance to Cryptococcus neoformans infection induced by chloroquine in a murine model of meningoencephalitis","volume":"41","author":"Mazzolla","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106807","article-title":"Antimalarials and amphotericin B interact synergistically and are new options to treat cryptococcosis","volume":"62","author":"Freitas","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.nmni.2026.101735_bib59","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.3390\/ijms26209953","article-title":"Assessing the anti-cryptococcus antifungal potential of artemisinin","volume":"26","author":"Maliehe","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmni.2026.101735_bib60","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.3390\/ijms26167909","article-title":"Exploring a therapeutic gold mine: the antifungal potential of the gold-based antirheumatic drug auranofin","volume":"26","author":"Ma","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nmni.2026.101735_bib61","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nri1255","article-title":"Immunity to fungal infections","volume":"4","author":"Romani","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib62","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nri2939","article-title":"Immunity to fungal infections","volume":"11","author":"Romani","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib63","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00264-13","article-title":"Macrophage M1\/M2 polarization dynamically adapts to changes in Cryptococcus neoformans infection","volume":"4","author":"Davis","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib64","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1128\/EC.00039-10","article-title":"Cryptococcal interactions with the host immune system","volume":"9","author":"Voelz","year":"2010","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.nmni.2026.101735_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007144","article-title":"Cryptococcus neoformans urease affects the outcome of intracellular pathogenesis by modulating phagolysosomal pH","volume":"14","author":"Fu","year":"2018","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.nmni.2026.101735_bib66","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3390\/microorganisms8020180","article-title":"Environmental factors that contribute to the maintenance of Cryptococcus neoformans pathogenesis","volume":"8","author":"Maliehe","year":"2020","journal-title":"Microorganisms"},{"key":"10.1016\/j.nmni.2026.101735_bib67","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00437-18","article-title":"The capsule of Cryptococcus neoformans modulates phagosomal pH through its acid-base properties","volume":"3","author":"De Leon-Rodriguez","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.nmni.2026.101735_bib68","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1073\/pnas.052702799","article-title":"Replication of Cryptococcus neoformans in macrophages is accompanied by phagosomal permeabilization and accumulation of vesicles containing polysaccharide in the cytoplasm","volume":"99","author":"Tucker","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nmni.2026.101735_bib69","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1128\/IAI.67.2.885-890.1999","article-title":"Cryptococcus neoformans resides in an acidic phagolysosome of human macrophages","volume":"67","author":"Levitz","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.nmni.2026.101735_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2023.101361","article-title":"Primaquine, an antimalarial drug that controls the growth of cryptococcal cells","volume":"33","author":"Madu","year":"2023","journal-title":"J Med Mycol"},{"key":"10.1016\/j.nmni.2026.101735_bib71","first-page":"275","article-title":"The repurposing of the antimalaria drug, primaquine, as a photosensitizer to inactivate cryptococcal cells","author":"Madu","year":"2021","journal-title":"Photochemistry"},{"key":"10.1016\/j.nmni.2026.101735_bib72","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1172\/JCI119688","article-title":"Chloroquine induces human mononuclear phagocytes to inhibit and kill Cryptococcus neoformans by a mechanism independent of iron deprivation","volume":"100","author":"Levitz","year":"1997","journal-title":"J Clin Investig"},{"key":"10.1016\/j.nmni.2026.101735_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcell.2021.658995","article-title":"Lysosome (dys)function in atherosclerosis \u2014 a big weight on the shoulders of a small organelle","volume":"9","author":"Marques","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.nmni.2026.101735_bib74","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI117119","article-title":"Chloroquine induces human macrophage killing of Histoplasma capsulatum by limiting the availability of intracellular iron and is therapeutic in a murine model of histoplasmosis","volume":"93","author":"Newman","year":"1994","journal-title":"J Clin Investig"},{"key":"10.1016\/j.nmni.2026.101735_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2016.00164","article-title":"Cryptococcus neoformans: tripping on acid in the phagolysosome","volume":"7","author":"DeLeon-Rodriguez","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.nmni.2026.101735_bib76","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1078\/0171-9335-00062","article-title":"Primaquine interferes with membrane recycling from endosomes to the plasma membrane through a direct interaction with endosomes which does not involve neutralisation of endosomal pH nor osmotic swelling of endosomes","volume":"79","author":"Van Weert","year":"2000","journal-title":"Eur J Cell Biol"},{"key":"10.1016\/j.nmni.2026.101735_bib77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1128\/AAC.43.2.233","article-title":"Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations","volume":"43","author":"Nosanchuk","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02345-17","article-title":"Copper acyl salicylate has potential as an anti-cryptococcus antifungal agent","volume":"62","author":"Ogundeji","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib79","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2249.2009.03893.x","article-title":"Innate immunity and inflammation - two facets of the same anti-infectious reaction","volume":"156","author":"Si-Tahar","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib80","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.nmni.2026.101735_bib81","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/322044","article-title":"Host\u2010pathogen interactions: the attributes of virulence","volume":"184","author":"Casadevall","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib82","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.tim.2017.10.005","article-title":"Quorum-sensing systems as targets for antivirulence therapy","volume":"26","author":"Defoirdt","year":"2018","journal-title":"Trends Microbiol"},{"key":"10.1016\/j.nmni.2026.101735_bib83","first-page":"1","article-title":"Recent advances in anti-virulence therapeutic strategies with a focus on dismantling bacterial membrane microdomains, toxin neutralization, quorum-sensing interference and biofilm inhibition","volume":"9","author":"Mart\u00ednez","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.nmni.2026.101735_bib84","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/glycob\/cwy030","article-title":"Unraveling synthesis of the cryptococcal cell wall and capsule","volume":"28","author":"Wang","year":"2018","journal-title":"Glycobiology"},{"key":"10.1016\/j.nmni.2026.101735_bib85","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760180057","article-title":"Cryptococcal pathogenic mechanisms: a dangerous trip from the environment to the brain","volume":"113","author":"Esher","year":"2018","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.nmni.2026.101735_bib86","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1128\/iai.63.8.3131-3136.1995","article-title":"Cryptococcus neoformans melanin and virulence: mechanism of action","volume":"63","author":"Wang","year":"1995","journal-title":"Infect Immun"},{"key":"10.1016\/j.nmni.2026.101735_bib87","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1128\/AAC.46.11.3394-3400.2002","article-title":"Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin","volume":"46","author":"van Duin","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib88","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1084\/jem.184.2.377","article-title":"Effect of the laccase gene, CNLAC1, on virulence of Cryptococcus neoformans","volume":"184","author":"Salas","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.nmni.2026.101735_bib89","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.2741\/A231","article-title":"Laccase and melanin in the pathogenesis of Cryptococcus neoformans","volume":"2","author":"Williamson","year":"1997","journal-title":"Front Biosci"},{"key":"10.1016\/j.nmni.2026.101735_bib90","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1099\/13500872-140-1-19","article-title":"The structure and function of fungal laccases","volume":"140","author":"Thurston","year":"1994","journal-title":"Microbiology"},{"key":"10.1016\/j.nmni.2026.101735_bib91","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1128\/EC.00103-15","article-title":"Virulence-associated enzymes of Cryptococcus neoformans","volume":"14","author":"Almeida","year":"2015","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.nmni.2026.101735_bib92","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12223-023-01088-2","article-title":"Production of laccase enzyme from Curvularia lunata MY3: purification and characterization","volume":"69","author":"Hamed","year":"2024","journal-title":"Folia Microbiol (Praha)"},{"key":"10.1016\/j.nmni.2026.101735_bib93","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jbiotec.2016.04.006","article-title":"A strategy for soluble overexpression and biochemical characterization of halo-thermotolerant bacillus laccase in modified E. coli","volume":"227","author":"Safarya","year":"2016","journal-title":"J Biotechnol"},{"key":"10.1016\/j.nmni.2026.101735_bib94","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0749.1993.tb00591.x","article-title":"Interaction between chemicals and melanin","volume":"6","author":"Larsson","year":"1993","journal-title":"Pigment Cell Res"},{"key":"10.1016\/j.nmni.2026.101735_bib95","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1128\/AAC.40.3.541","article-title":"Susceptibility of melanized and nonmelanized Cryptococcus neoformans to the melanin-binding compounds trifluoperazine and chloroquine","volume":"40","author":"Wang","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib96","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1348-0421.2003.tb03395.x","article-title":"Effects of melanin upon susceptibility of Cryptococcus to antifungals","volume":"47","author":"Ikeda","year":"2003","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib97","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1128\/IAI.01065-08","article-title":"Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans","volume":"77","author":"Charlier","year":"2009","journal-title":"Infect Immun"},{"key":"10.1016\/j.nmni.2026.101735_bib98","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01101-14","article-title":"Invasion of the central nervous system by Cryptococcus neoformans requires a secreted fungal metalloprotease","volume":"5","author":"Vu","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib99","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.01249-20","article-title":"An antivirulence approach for preventing cryptococcus neoformans from crossing the blood-brain barrier via novel natural product inhibitors of a fungal metalloprotease","volume":"11","author":"Aaron","year":"2020","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib100","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3390\/jof5020031","article-title":"The spectrum of interactions between Cryptococcus neoformans and bacteria","volume":"5","author":"Mayer","year":"2019","journal-title":"J Fungi"},{"key":"10.1016\/j.nmni.2026.101735_bib101","doi-asserted-by":"crossref","first-page":"384","DOI":"10.15698\/mic2017.11.599","article-title":"Breaking the bad: bacillus blocks fungal virulence factors","volume":"4","author":"Mayer","year":"2017","journal-title":"Microb Cell"},{"key":"10.1016\/j.nmni.2026.101735_bib102","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1080\/21505594.2015.1066962","article-title":"Fungal serotype-specific differences in bacterial-yeast interactions","volume":"6","author":"Abdulkareem","year":"2015","journal-title":"Virulence"},{"key":"10.1016\/j.nmni.2026.101735_bib103","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1038\/s41598-023-32140-3","article-title":"Differentiated extracts from freshwater and terrestrial mollusks inhibit virulence factor production in Cryptococcus neoformans","volume":"1","author":"Guti\u00e9rrez-G\u00f3ngora","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.nmni.2026.101735_bib104","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02841-23","article-title":"Natural compounds from freshwater mussels disrupt fungal virulence determinants and influence fluconazole susceptibility in the presence of macrophages in Cryptococcus neoformans","volume":"12","author":"Guti\u00e9rrez-G\u00f3ngora","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.nmni.2026.101735_bib105","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01862-15","article-title":"Analysis of the protein kinase A-regulated proteome of C. neoformans identifies a role for the ubiquitin\u2013proteasome pathway in capsule formation","volume":"7","author":"Geddes","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2015.00836","article-title":"Role of Sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development","volume":"6","author":"Rella","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.nmni.2026.101735_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fcimb.2021.739027","article-title":"Cryptococcus neoformans \u0394sgl1 vaccination requires either CD4+ or CD8+ T cells for complete host protection","volume":"11","author":"Normile","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.nmni.2026.101735_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.581750","article-title":"Animal models of Cryptococcus neoformans in identifying immune parameters associated with primary infection and reactivation of latent infection","volume":"11","author":"Normile","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib109","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41385-022-00570-3","article-title":"Vaccine protection by Cryptococcus neoformans \u0394sgl1 is mediated by \u03b3\u03b4 T cells via TLR2 signaling","volume":"15","author":"Normile","year":"2022","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib110","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1007\/s00467-023-05969-z","article-title":"Live attenuated vaccines in patients receiving immunosuppressive agents","volume":"38","author":"Kamei","year":"2023","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.nmni.2026.101735_bib111","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-021-00294-8","article-title":"Vaccines for human fungal diseases: close but still a long way to go","volume":"6","author":"Oliveira","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.nmni.2026.101735_bib112","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/jof1030397","article-title":"Masking the pathogen: evolutionary strategies of fungi and their bacterial counterparts","volume":"1","author":"Park","year":"2015","journal-title":"J Fungi"},{"key":"10.1016\/j.nmni.2026.101735_bib113","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/j.vaccine.2010.12.134","article-title":"Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis","volume":"29","author":"Chow","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.nmni.2026.101735_bib114","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1128\/iai.65.4.1158-1164.1997","article-title":"Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody","volume":"65","author":"Zhang","year":"1997","journal-title":"Infect Immun"},{"key":"10.1016\/j.nmni.2026.101735_bib115","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.4049\/jimmunol.166.2.1087","article-title":"A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection","volume":"166","author":"Fleuridor","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib116","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/CVI.00130-08","article-title":"Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan","volume":"15","author":"Datta","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib117","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1128\/EC.00399-06","article-title":"Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans","volume":"6","author":"Baker","year":"2007","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.nmni.2026.101735_bib118","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1128\/EC.05138-11","article-title":"Cell wall chitosan is necessary for virulence in the opportunistic pathogen Cryptococcus neoformans","volume":"10","author":"Baker","year":"2011","journal-title":"Eukaryot Cell"},{"key":"10.1016\/j.nmni.2026.101735_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.01905-15","article-title":"Protection against experimental cryptococcosis following vaccination with glucan particles containing cryptococcus alkaline extracts","volume":"6","author":"Specht","year":"2015","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib120","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00547-16","article-title":"Induction of protective immunity to cryptococcal infection in mice by a heat-killed, chitosan-deficient strain of Cryptococcus neoformans","volume":"7","author":"Upadhya","year":"2016","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib121","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.vaccine.2019.10.051","article-title":"Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens","volume":"38","author":"Hester","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.nmni.2026.101735_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mbio.03367-21","article-title":"Protection of mice against experimental cryptococcosis by synthesized peptides delivered in glucan particles","volume":"13","author":"Specht","year":"2022","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-025-01079-z","article-title":"Developing mRNA lipid nanoparticle vaccine effective for cryptococcosis in a murine model","volume":"10","author":"Li","year":"2025","journal-title":"npj Vaccines"},{"key":"10.1016\/j.nmni.2026.101735_bib124","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02087-18","article-title":"Cryptococcus neoformans cda1 and its chitin deacetylase activity are required for fungal pathogenesis","volume":"9","author":"Upadhya","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib125","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01872-17","article-title":"Vaccination with recombinant Cryptococcus proteins in glucan particles protects mice against cryptococcosis in a manner dependent upon mouse strain and cryptococcal species","volume":"8","author":"Specht","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.nmni.2026.101735_bib126","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41541-023-00606-0","article-title":"Immunological correlates of protection following vaccination with glucan particles containing Cryptococcus neoformans chitin deacetylases","volume":"8","author":"Wang","year":"2023","journal-title":"npj Vaccines"},{"key":"10.1016\/j.nmni.2026.101735_bib127","series-title":"Immunobiology: the immune system in health and disease","author":"Janeway","year":"2001"},{"key":"10.1016\/j.nmni.2026.101735_bib128a","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/imr.12066","article-title":"CD4+ T cell depletion in HIV Infection: mechanisms of immunological failure","volume":"254","author":"Okoye","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.nmni.2026.101735_bib128b","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/eji.1830220617","article-title":"Cytokine enhancement of complement-dependent phagocytosis by macrophages: synergy of tumor necrosis factor-\u03b1 and granulocyte-macrophage colony-stimulating factor for phagocytosis of Cryptococcus neoformans","volume":"22","author":"Collins","year":"1992","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jof3030035","article-title":"Innate immune responses to cryptococcus","volume":"3","author":"Heung","year":"2017","journal-title":"J Fungi"},{"key":"10.1016\/j.nmni.2026.101735_bib130","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3389\/fimmu.2019.01725","article-title":"TNF-\u03b1-producing Cryptococcus neoformans exerts protective effects on host defenses in murine pulmonary cryptococcosis","volume":"10","author":"Fa","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.nmni.2026.101735_bib131","first-page":"123","article-title":"Contribution of interferon-\u03b3 in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans","volume":"13","author":"Kawakami","year":"1996","journal-title":"Pathog Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib132","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1086\/420829","article-title":"Recombinant interferon-\u03b3lb as adjunctive therapy for AIDS-related acute cryptococcal meningitis","volume":"189","author":"Pappas","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.nmni.2026.101735_bib133","first-page":"1105","article-title":"Adjunctive interferon- immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial","volume":"26","author":"Jarvis","year":"2012","journal-title":"Eur PMC Funders Gr"},{"key":"10.1016\/j.nmni.2026.101735_bib134","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1128\/IAI.69.5.3410-3412.2001","article-title":"Passive immunization with melanin-binding monoclonal antibodies prolongs survival of mice with lethal Cryptococcus neoformans infection","volume":"69","author":"Rosas","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.nmni.2026.101735_bib135","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/AAC.49.3.952-958.2005","article-title":"Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis","volume":"49","author":"Larsen","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nmni.2026.101735_bib136","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1469-0691.2011.03741.x","article-title":"Immunotherapy of Cryptococcus infections","volume":"18","author":"Antachopoulos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.nmni.2026.101735_bib137","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/617459","article-title":"Traditional medicines in Africa: an appraisal of ten potent African medicinal plants","volume":"2013","author":"Mahomoodally","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.nmni.2026.101735_bib138","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/525340","article-title":"Historical perspective of traditional indigenous medical practices: the current renaissance and conservation of herbal resources","volume":"2014","author":"Pan","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.nmni.2026.101735_bib139","article-title":"The high cost of prescription drugs: causes and solutions","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.nmni.2026.101735_bib140","article-title":"The antifungal effects of berberine and its proposed mechanism of action through CYP51 inhibition, as predicted by molecular docking and binding analysis","volume":"29","author":"Zhang","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.nmni.2026.101735_bib141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/molecules26113476","article-title":"Investigation of antifungal mechanisms of thymol in the human fungal pathogen, Cryptococcus neoformans","volume":"26","author":"Jung","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.nmni.2026.101735_bib142","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/jam.12966","article-title":"Curcumin enhances the activity of fluconazole against Cryptococcus gattii\u2010induced cryptococcosis infection in mice","volume":"120","author":"da Silva","year":"2016","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.nmni.2026.101735_bib143","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1440-0960.2002.00590.x","article-title":"Treatment of interdigital Tinea pedis with 25% and 50% tea tree oil solution: a randomized, placebo-controlled, blinded study","volume":"43","author":"Satchell","year":"2002","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.nmni.2026.101735_bib144","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/0019-5154.43209","article-title":"Andomized comparative clinical trial of Artemisia sieberi 5% lotion and clotrimazole 1% lotion for the treatment of pityriasis versicolor","volume":"53","author":"Rad","year":"2008","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.nmni.2026.101735_bib145","article-title":"Comparison between the Efficacy of Nigella sativa -honey and clotrimazole on vulvovaginal candidiasis: a randomized clinical trial","volume":"2022","author":"Norouzi","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.nmni.2026.101735_bib146","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4081\/jphia.2023.2625","article-title":"The 2nd international conference on public health in Africa 12-15 December 2022, Kigali, Rwanda","volume":"14","author":"Colizzi","year":"2023","journal-title":"J Publ Health Afr"},{"key":"10.1016\/j.nmni.2026.101735_bib147","doi-asserted-by":"crossref","DOI":"10.1016\/j.mycmed.2023.101438","article-title":"Fungal diseases in Africa: closing the gaps in diagnosis and treatment through implementation research and advocacy","volume":"33","author":"Bongomin","year":"2023","journal-title":"J Mycol Med"},{"key":"10.1016\/j.nmni.2026.101735_bib148","doi-asserted-by":"crossref","DOI":"10.1093\/mmy\/myad141","article-title":"The Nairobi declaration 2023: a commitment to address deadly yet neglected fungal diseases in Africa","volume":"62","author":"Osaigbovo","year":"2024","journal-title":"Med Mycol"},{"key":"10.1016\/j.nmni.2026.101735_bib149","series-title":"Rapid advise: diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children","year":"2011"},{"key":"10.1016\/j.nmni.2026.101735_bib150","series-title":"Supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection","article-title":"Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children","year":"2018"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297526000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297526000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:46:09Z","timestamp":1778834769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2052297526000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":149,"alternative-id":["S2052297526000399"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2026.101735","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the current anti-Cryptococcus antifungals and emerging treatment strategies","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2026.101735","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101735"}}